• Search

Discovery Stems From Here

Find your tools for building human cell-based models & screening assays

Welcome to Axol Bioscience


Our mission is to create the best human cell biology research tools, to advance medical research and drug discovery

Latest News

  • Axol Bioscience launch Human iPSC-derived Atrial Cardiomyocytes

    Cambridge, UK – (17th July 2018) – Axol Bioscience, the human cell culture specialists, provide highly validated primary cells and iPSC-derived cells together with optimised media and growth supplements, launch their Human iPSC-derived Atrial Cardiomyocytes for the discovery and development of novel treatments and advancing our understanding of cardiovascular disease.

  • iPSC-derived sensory neurons for the study of chemotherapy-induced neuropathic pain

    Neuropathic pain is a debilitating side effect of many commonly-used chemotherapy drugs, and in severe cases can result in the discontinuation of a cancer treatment. By understanding the mechanisms through which chemotherapeutics induce neuropathic pain, researchers aim to develop effective treatments designed specifically to alleviate the condition. These will combat the dose-limitation imposed on chemotherapeutics, as well as offering utility for conditions including multiple sclerosis, diabetes and HIV.

  • Understanding the mechanisms of chemotherapy induced neuropathic pain using iPSC-derived sensory neurons

    Many commonly used chemotherapy drugs cause unpleasant side effects and complications. Of these, neuropathic pain can be particularly debilitating. Most of the current treatments for neuropathic pain are medications that were originally approved for other health disorders, such as anti-depressants and anti-seizure drugs. These have their own accompanying problems, and since no single drug is effective against all forms of neuropathic pain, it is essential that new therapeutic agents are developed specifically for the treatment of this condition.

  • Layers of complexity: differentiating iPSCs into derivatives of the embryonic germ layers

    Through the previous blogs in this series, we have understood the challenges which somatic cells face when changing their career path to become induced pluripotent stem cells (iPSCs), the ways in which we can induce this change, and how we might assess whether this is the right career for the cells through pluripotency and differentiation assays.

  • Assessing the pluripotency and the differentiation potential of iPSCs

    In our previous blog we likened somatic cell reprogramming to a career change. Once a somatic cell has been converted to an induced pluripotent stem cell (iPSC), the next stage in the process can be thought of as an appraisal or performance review. This is essential to confirming that the reprogrammed cell is behaving as expected.